Department of Biostatistics, Harvard School of Public Health, 665 Huntington Ave, Building I, 415, Boston, MA 02115-6017, USA.
Pediatrics. 2010 Feb;125(2):e250-60. doi: 10.1542/peds.2009-1112. Epub 2010 Jan 18.
Antiretroviral (ARV) drugs are routinely provided to HIV-infected pregnant women to prevent HIV mother-to-child transmission. Although ARV use has significantly reduced mother-to-child transmission to <2% in the United States, it remains crucial to monitor uninfected infants and children for adverse consequences of in utero ARV exposure.
We studied neurodevelopmental function in HIV-exposed uninfected children who were enrolled in Pediatric AIDS Clinical Trials Group 219/219C, a multisite, prospective, cohort study. Mental and motor functioning were assessed with the Bayley Scales of Infant Development (BSID), first and second editions. ARV exposure information was collected during pregnancy or within the first years of life. Linear regression methods were used to evaluate the association of in utero ARV exposure on Mental Developmental Index and Psychomotor Developmental Index at 2 years of age, controlling for demographic factors (age, gender, and race/ethnicity) and potential confounders: test version, primary language, primary caregiver, caregiver education level, low birth weight, geographic and urban/rural location, birth year, and maternal illicit drug use.
Among 1840 infants who were born between 1993 and 2006, 1694 (92%) were exposed to ARV in utero and 146 (8%) were not exposed. After controlling for confounders, children who were exposed in utero to any ARV did not have lower Mental Developmental Index and Psychomotor Developmental Index scores than unexposed children. Among low birth weight infants, significantly higher BSID scores were observed for prenatally ARV-exposed than unexposed children. Maternal illicit drug use was reported for 17% of mothers but was not associated with BSID scores.
Mental and motor functioning scores were not lower for infants with in utero ARV exposure compared with no exposure. Although these results are reassuring, continued evaluation of uninfected children with in utero ARV exposure for long-term adverse outcomes is important.
抗逆转录病毒(ARV)药物通常提供给感染 HIV 的孕妇,以预防 HIV 母婴传播。尽管在美国,ARV 的使用已显著将母婴传播率降低到<2%,但仍需密切监测未感染的婴儿和儿童,以了解宫内 ARV 暴露的不良后果。
我们研究了在儿科艾滋病临床试验组 219/219C 中入组的 HIV 暴露但未感染的儿童的神经发育功能,这是一项多中心、前瞻性队列研究。使用贝利婴幼儿发展量表(BSID)的第一版和第二版评估精神和运动功能。在怀孕期间或生命的头几年收集 ARV 暴露信息。线性回归方法用于评估宫内 ARV 暴露对 2 岁时精神发育指数和精神运动发育指数的影响,控制人口统计学因素(年龄、性别和种族/族裔)和潜在混杂因素:测试版本、主要语言、主要照顾者、照顾者教育水平、低出生体重、地理位置和城乡/农村位置、出生年份和母亲非法药物使用。
在 1993 年至 2006 年间出生的 1840 名婴儿中,1694 名(92%)在宫内暴露于 ARV,146 名(8%)未暴露。在控制混杂因素后,宫内暴露于任何 ARV 的儿童的精神发育指数和精神运动发育指数得分均不低于未暴露的儿童。在低出生体重婴儿中,与未暴露的婴儿相比,产前 ARV 暴露的婴儿的 BSID 得分显著更高。17%的母亲报告了滥用药物,但这与 BSID 得分无关。
与未暴露的婴儿相比,宫内 ARV 暴露的婴儿的精神和运动功能评分没有更低。尽管这些结果令人放心,但仍需继续评估宫内接受 ARV 暴露的未感染儿童是否存在长期不良后果。